Abstracts tagged "registry"

Abstract Number: 0581 • ACR Convergence 2024
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 2412 • ACR Convergence 2024
Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database
Irene Altabás-González¹, Íñigo Rúa-Figueroa², Coral Mouriño³, Ivonne Lourdes Mamani⁴, Karen Roberts⁵, Julia Martínez-Barrio⁶, María Galindo-Izquierdo⁷, Jaime Calvo-Alen⁸, MARIA CELIA ERAUSQUIN ARRUABARRENA⁹, Belen Serrano-Benavente⁶, Irene Carrión-Barberà¹⁰, Esther Uriarte-Isacelaya¹¹, Eva Tomero Muriel¹², Mercedes Freire González¹³, Ricardo Blanco-Alonso¹⁴, Eva Salgado-Pérez¹⁵, Paloma Vela-Casasempere¹⁶, Antonio Fernández-Nebro¹⁷, Alejandro Olive¹⁸, Clara Sanguesa¹⁹, Javier Narvaez-García²⁰, Raúl Menor Almagro²¹, José Rosas-Gómez de Salazar²², José Ángel Hernández Beriain²³, Francisco j. Manero-Ruiz²⁴, Elena Aurrecoechea²⁵, Carlos Montilla²⁶, gema Bonilla²⁷, Oihane Ibarguengoitia Barrena²⁸, Vicenç Torrente-Segarra²⁹, Ana Paula Cacheda³⁰, María García-Villanueva³¹, Clara Moriano³², Loreto Horcada³³, Nuria Lozano-rivas³⁴, Cristina Bohorquez³⁵ and José María Pego-Reigosa³⁶, and RELESSER-Group, ¹Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ²Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴COMPLEJO HOSPITALARIO UNIVERSITARIO DE VIGO, Pontevedra, Spain, ⁵Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital 12 de Octubre, Madrid, Madrid, Spain, ⁸Hospital Universitario de Araba, Araba, Spain, ⁹Gob Canarias, Tenerife, Canarias, Spain, ¹⁰Hospital del Mar, Barcelona, Spain, ¹¹Hospital Univeritario de Donostia, San Sebastián, Spain, ¹²La Princesa Hospital, Madrid, Madrid, Spain, ¹³Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ¹⁵Complejo Hospitalario de Orense, Ourense, Spain, ¹⁶Hospital General Universitario Alicante, Alicante, Spain, ¹⁷Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ¹⁸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ²¹Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ²²Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ²³Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, ²⁴H. Miguel Servet, Zaragoza, Spain, ²⁵Hospital de Sierrallana, Torrelavega, Spain, ²⁶Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁷Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁸Rheumatology Division, Galdakao-Usansolo University Hospital, Galdako, Spain, ²⁹Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³⁰Hospital Universitario Son Llàtzer, Mallorca, Spain, ³¹Hospital Ramón y Cajal, MADRID, Madrid, Spain, ³²Hospital León, LEON, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Virgen de la Arrixaca University Hospital, Murcia, Spain, ³⁵Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ³⁶Galicia Health Service (SERGAS), Vigo, Spain
Background/Purpose: In systemic lupus erythematosus (SLE), there is not a standardized and validated definition of states of moderate and severe SLE activity. The aim of…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 1671 • ACR Convergence 2024
Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Louise Nielung¹, Merete Hetland², Lone Skov³, Hans Albert Frandsen⁴, Lene Dreyer⁵ and Bente Glintborg⁶, ¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Gentofte, Denmark, ⁴Patient Partner, Frederiksberg, Denmark, ⁵Department of Rheumatology, Aalborg UnIversity Hospital, København, Denmark, ⁶DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…
Abstract Number: 2618 • ACR Convergence 2024
Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Danielle Bullock⁷, Jon Burnham⁸, Tzielan Lee⁹, Daniel Lovell¹⁰, Ted Wimmel¹¹, Delores Mincarelli¹¹, Mayur Patil¹², Magen Phillips¹¹ and Esi Morgan¹³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷M Health Fairview Masonic Children’s Hospital, Minneapolis, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Hive Networks, Newport, ¹²VSquare Infotech Inc, Edison, NJ, ¹³Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network with a vision that children with rheumatic disease will have…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 1869 • ACR Convergence 2024
Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases
Shunya Kaneshita¹, Christina Chambers², Diana Johnson¹, Arthur Kavanaugh¹, Richard Garfein¹ and Gretchen Bandoli¹, ¹University of California San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant women are particularly at risk of severe Coronavirus disease 2019 (COVID-19) infection, which is why the Centers for Disease Control and Prevention (CDC)…
Abstract Number: 2621 • ACR Convergence 2024
Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records
David Cheng¹, Vidul Panickan², Andrew Cagan³, Gregory McDermott⁴, Mary Jeffway³, Ying Qi⁵, Feng Liu³, Michael Weinblatt⁶, Nancy Shadick⁵, Tianxi Cai⁷ and Katherine Liao³, ¹Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Brookline, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…
Abstract Number: 0655 • ACR Convergence 2024
Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry
Minjee Park¹, Sofia Pedro², Jean-Francois Ricci¹, Kaleb Michaud³ and Patti Katz⁴, ¹Alira Health, Basel, Switzerland, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴UCSF, San Rafael, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge…
Abstract Number: 1875 • ACR Convergence 2024
Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
Liya Stolyar¹, Diane Mar², Yuhan Liu³, Esther Velasquez⁴, orr Sharpe⁵, Michael Weisman⁶, Liron Caplan⁷ and suzanne Tamang⁸, ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Palo Alto VA Medical Center/Stanford University Medical Center, Palo Alto, CA, ³Stanford Medicine Quantitative Sciences Unit, Palo Alto, CA, ⁴Stanford Center for Population Health Sciences, Palo Alto, CA, ⁵Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁶Stanford University, Los Angeles, CA, ⁷Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ⁸Stanford University, Atherton, CA
Background/Purpose: Acute exposure to air pollution has been associated with flares of psoriasis and chronic inflammatory arthritides in prior studies. However, the impact of air pollution,…
Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
James Bistolarides¹, Vidya Sivaraman², Else Bosman³, Linda Wagner-Weiner⁴, Kimberly Morishita⁵, James Nocton¹, Melodee Liegl¹, Amy Pan¹ and David Cabral⁶, and PedVas Investigators Network, ¹Medical College of Wisconsin, Milwaukee, WI, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³UBC, Vancouver, BC, Canada, ⁴University of Chicago, Chicago, IL, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
Abstract Number: 0688 • ACR Convergence 2024
Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching
Enrico De Lorenzis¹, Gerlando Natalello², Fabio Cacciapaglia³, Rossella De Angelis⁴, Edoardo Cipolletta⁵, Veronica Codullo⁶, Giacomo De Luca⁷, Dilia Giuggioli⁸, Francesca Ingegnoli⁹, Valeria Riccieri¹⁰, Maria Antonietta D'Agostino¹¹, Clodoveo Ferri¹², Marco Matucci Cerinic¹³ and Silvia Laura Bosello¹⁴, ¹Catholic University of the Sacred Heart, Roma, Rome, Italy, ²Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Polytechnic University of Marche, Ancona, Italy, Ancona, Italy, ⁵Polytechnic University of Marche, Ancona, Italy, ⁶Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁷Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁸Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁹Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Research Center for Environmental Health, Università degli Studi di Milano, Milan, Italy, ¹⁰Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, ¹¹Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ¹²Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹³Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: The prescription of Mycophenolate Mofetil (MMF) represents the primary treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and is an option…
Abstract Number: 1902 • ACR Convergence 2024
Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Merete Hetland² and Bente Glintborg³, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Clinical trials have provided robust evidence of the efficacy of ixekizumab, an IL-17 inhibitor, in improving the signs and symptoms of psoriatic arthritis (PsA)…
Abstract Number: 2680 • ACR Convergence 2024
Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE
Omer Pamuk¹, Jessica Fitzpatrick², Jing Li³, Gabriela Schmajuk⁴ and Marina Magrey⁵, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a very heterogeneous presentation. Thrombocytopenia (TP) is an infrequent presentation in patients with SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].